{'52WeekChange': 0.25051343,
 'SandP52WeekChange': 0.0644362,
 'address1': "77 Sir John Rogerson's Quay",
 'address2': 'Block C Grand Canal Docklands',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.15,
 'askSize': 800,
 'averageDailyVolume10Day': 337687,
 'averageVolume': 314560,
 'averageVolume10days': 337687,
 'beta': 1.836974,
 'beta3Year': None,
 'bid': 12.12,
 'bidSize': 900,
 'bookValue': 6.39,
 'category': None,
 'circulatingSupply': None,
 'city': 'Dublin',
 'companyOfficers': [],
 'country': 'Ireland',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.35,
 'dayLow': 11.95,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.803,
 'enterpriseToRevenue': 201.741,
 'enterpriseValue': 155139008,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '353 1 902 3510',
 'fiftyDayAverage': 11.046715,
 'fiftyTwoWeekHigh': 17.63,
 'fiftyTwoWeekLow': 6.71,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 16061550,
 'forwardEps': -1.95,
 'forwardPE': -6.246154,
 'fromCurrency': None,
 'fullTimeEmployees': 51,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00029,
 'heldPercentInstitutions': 0.97080004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/prothena.com',
 'longBusinessSummary': 'Prothena Corporation plc, a clinical-stage '
                        'neuroscience company, focuses on discovery and '
                        'development of novel therapies for life-threatening '
                        'diseases in the United States. The company is '
                        'involved in developing PRX002/RG7935 that is in Phase '
                        "II clinical trial for treating Parkinson's disease "
                        'and other related synucleinopathies; and PRX004, an '
                        'antibody that is in Phase I clinical trial for the '
                        'treatment of ATTR amyloidosis. Its discovery-stage '
                        "programs include Tau for treating Alzheimer's "
                        'disease, progressive supranuclear palsy, '
                        'frontotemporal dementia, chronic traumatic '
                        'encephalopathy, and other tauopathies; AÃ\x9f, or '
                        'Amyloid Beta, a protein for the treatment of '
                        "Alzheimer's disease; TDP-43 for amyotrophic lateral "
                        'sclerosis and frontotemporal dementia; and other '
                        'products for neurodegeneration. The company has a '
                        'license, development, and commercialization agreement '
                        'with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche '
                        'Inc. to develop and commercialize antibodies that '
                        'target alpha-synuclein; and a collaboration agreement '
                        'with Bristol-Myers Squibb to develop antibodies. '
                        'Prothena Corporation plc was founded in 2012 and is '
                        'based in Dublin, Ireland.',
 'longName': 'Prothena Corporation plc',
 'market': 'us_market',
 'marketCap': 486120864,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_215515336',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -80381000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.19,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -1.16,
 'phone': '353 1 236 2500',
 'previousClose': 12.32,
 'priceHint': 2,
 'priceToBook': 1.9061034,
 'priceToSalesTrailing12Months': 632.1468,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.35,
 'regularMarketDayLow': 11.95,
 'regularMarketOpen': 12.19,
 'regularMarketPreviousClose': 12.32,
 'regularMarketPrice': 12.19,
 'regularMarketVolume': 210595,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39911400,
 'sharesPercentSharesOut': 0.033299997,
 'sharesShort': 1330060,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1088725,
 'shortName': 'Prothena Corporation plc',
 'shortPercentOfFloat': 0.0436,
 'shortRatio': 3.71,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'PRTA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.015,
 'twoHundredDayAverage': 11.570576,
 'volume': 210595,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.prothena.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '2'}